Johnson & Johnson collaborates with Sail Biomedicines on in vivo CAR-T therapies

WHAT CHINWAGY KNOWS

The collaboration
is confirmed.

Johnson & Johnson announced strategic agreements and a collaboration with Sail Biomedicines to advance Sail’s in vivo CAR-T platform and immune-mediated disease programs. The arrangement includes collaboration through Janssen Biotech, an equity investment and an exclusive option to acquire Sail.

Current status

Official collaboration

Known availability

The published source describes the collaboration; timing details remain under review.

Place

New Brunswick, United States

Source checked

September 26, 2026